You are here: Industry Insights > teva

News List

Teva Pharmaceutical Industries (TEVA) Given a $11.00 Price Target at Royal Bank Of Canada americanbankingnews
December 04, 2017
Teva Pharmaceutical Industries on Wednesday released a study to clients and investors that received a target price of $ 11.00 from Royal Bank Of Canada stock analysts.
Stellar results for Novartis, Teva anti-CGRP migraine drugs pharmatimes
December 01, 2017
Fifty percent of patients taking Novartis’ erenumab in a Phase III clinical trial had their migraine days cut by at least half, according to the data.
Teva Expected to Fire Up to 1,700 Workers in Israel, U.S biospace
November 28, 2017
Kåre Schultz, the new chief executive officer of Teva Pharmaceuticals will probably be likened to Dr. Seuss’ infamous character The Grinch as he reportedly plans to fire more than 1,000 employees this holiday season.
Teva looks set to axe thousands of positions and a big name pharmafile
November 24, 2017
Teva’s troubled year needs little detailing, those following the company have seen it lurch from one piece of bad news to another.
Teva looks to sell generics in China through joint venture with Guangzhou Pharma: Bloomberg fiercepharma
November 07, 2017
As the world’s largest generics maker, Teva still doesn’t have much of a presence in China, even though it is a country relies heavily on generics.
Teva to set up JV with Guangzhou Pharma biospectrumasia
November 07, 2017
Guangzhou Pharma is already seeing the benefits of China’s determination to speed up approvals.
Teva’s woes continue, as shares sink to 17-year low on Q3 results pharmafile
November 03, 2017
Spare a thought for Kare Schultz, he agreed to take on the position of CEO at Teva at the start of September and, reportedly, arrived for his first day of work at the company yesterday.
Teva under investigation over illegal rebate offers to Ontario pharmacies pharmafile
October 23, 2017
Israeli drugmaker Teva has again become embroiled in a scandal investigated by the Ontario government for allegedly bribing pharmacies to stock its opioid medications by offering illegal payments.
Teva to sell assets in global women’s health business for $1.38bn pharmaceufical-technology
September 20, 2017
Teva Pharmaceutical Industries has entered two agreements to divest the remaining stake in its specialist global women’s health business for $1.38bn.
Teva to sell its remaining women health biz assets for $1.38bn biospectrumasia
September 20, 2017
The drug maker plans to use the proceeds of the sale, combined with the $1.1 billion it received from the recent sale of its Paragard IUD asset announced last week, to pay down debt

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page